PUBLIC COMPANY
saveEisai Co Ltd
updated 2mo ago
Myōan Eisai or Yōsai was a Japanese Buddhist priest, credited with founding the Rinzai school, the Japanese line of the Linji school of Zen Buddhism. In 1191, he introduced this Zen approach to Japan, following his trip to China from 1187 to 1191, during which he was initiated into the Linji school by the master Hsü an. It is also said that he popularized green tea in Japan, following this same trip. He was also the founding abbot of Shōfuku-ji and Kennin-ji, two of the earliest Zen temples in Japan. He is often known simply as Eisai/Yōsai Zenji (栄西禅師), literally "Zen master Eisai".
community read0 votes
🐶 often sniffed alongside
top 8- tagOncology18 co-mentions · 2 sources
- tagInfectious Disease2 co-mentions · 2 sources
- tagBreast Cancer2 co-mentions · 2 sources
- tagColorectal Cancer2 co-mentions · 2 sources
- tagMelanoma2 co-mentions · 2 sources
- tagFGFR2 co-mentions · 1 sources
- druglenvatinib mesylate2 co-mentions · 2 sources
- druglenvatinib2 co-mentions · 2 sources
pipeline
18
marketed
7
phase 3
1
catalysts ytd
4
approvals ytd
2
recalls ytd
0
Pipeline(18)
view full pipeline →pipeline depth18 products
6Phase 13Phase 21Phase 37Marketed1Unknown
Marketed
Aricept
Dementia Associated With Alzheimer's Disease
Marketederibulin mesylate
Liposarcoma
Marketedlecanemab
Alzheimer's Disease
Amyloid-beta precursor protein
Marketedlemborexant
Insomnia
Marketedlenvatinib mesylate
Renal Cell Carcinoma
Vascular endothelial growth factor receptor
Marketedrabeprazole sodium DR
Acid Indigestion (Heartburn/Pyrosis)
Marketedrufinamide
Lennox-Gastaut Syndrome
Phase 3etalanetug
Dementia
Phase 2farletuzumab ecteribulin
Triple-Negative Breast Cancer (TNBC)
Phase 2foscenvivint
Colorectal Cancer
Phase 2irsenontrine maleate
Lewy Body Dementia
Phase 1E-1018
Malaria
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
- phase2A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy
- phase2A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
- phase2A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer
- phase3Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])
- phase2A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- phase3AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
- —A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology
🐶 Hiring Signal
News
no news has mentioned this company yet
Data sources
Found something off?
comments(0)
5-min edit window · permanent after that